Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative by Dunton, Charles J. et al.
University of Kentucky 
UKnowledge 
Markey Cancer Center Faculty Publications Markey Cancer Center 
8-10-2021 
Salvaging Detection of Early-Stage Ovarian Malignancies When 
CA125 Is Not Informative 
Charles J. Dunton 
Aspira Women’s Health, Inc. 
Megan L. Hutchcraft 
University of Kentucky, megan.hutchcraft@uky.edu 
Rowan G. Bullock 
Aspira Women’s Health, Inc. 
Lesley E. Northrop 
Aspira Women’s Health, Inc. 
Frederick R. Ueland 
University of Kentucky, fuela0@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub 
 Part of the Obstetrics and Gynecology Commons, and the Oncology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Dunton, Charles J.; Hutchcraft, Megan L.; Bullock, Rowan G.; Northrop, Lesley E.; and Ueland, Frederick R., 
"Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative" (2021). 
Markey Cancer Center Faculty Publications. 166. 
https://uknowledge.uky.edu/markey_facpub/166 
This Article is brought to you for free and open access by the Markey Cancer Center at UKnowledge. It has been 
accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not 
Informative 
Digital Object Identifier (DOI) 
https://doi.org/10.3390/diagnostics11081440 
Notes/Citation Information 
Published in Diagnostics, v. 11, issue 8, 1440. 
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. 
This article is an open access article distributed under the terms and conditions of the Creative 
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
This article is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/166 
diagnostics
Article
Salvaging Detection of Early-Stage Ovarian Malignancies
When CA125 Is Not Informative
Charles J. Dunton 1,2 , Megan L. Hutchcraft 3 , Rowan G. Bullock 1,*, Lesley E. Northrop 1
and Frederick R. Ueland 3


Citation: Dunton, C.J.; Hutchcraft,
M.L.; Bullock, R.G.; Northrop, L.E.;
Ueland, F.R. Salvaging Detection of
Early-Stage Ovarian Malignancies
When CA125 Is Not Informative.
Diagnostics 2021, 11, 1440. https://
doi.org/10.3390/diagnostics11081440
Academic Editor: Edward J. Pavlik
Received: 30 June 2021
Accepted: 6 August 2021
Published: 10 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Aspira Women’s Health, Inc., 12117 Bee Caves Road, Building III, Suite 100, Austin, TX 78738, USA;
cdunton1@aspirawh.com (C.J.D.); lnorthrop@aspirawh.com (L.E.N.)
2 The Women’s Hospital, Evansville, IN 47630, USA
3 Division of Gynecologic Oncology, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA;
megan.hutchcraft@uky.edu (M.L.H.); fuela0@uky.edu (F.R.U.)
* Correspondence: rbullock@aspirawh.com; Tel.: +1-(512)-519-0408
Abstract: Background: Ovarian cancer is the deadliest gynecologic cancer, with no recommended
screening test to assist with early detection. Cancer antigen 125 (CA125) is a serum biomarker com-
monly used by clinicians to assess preoperative cancer risk, but it underperforms in premenopausal
women, early-stage malignancies, and several histologic subtypes. OVA1 is a multivariate index
assay that combines CA125 and four other serum proteins to assess the malignant risk of an adnexal
mass. Objective: To evaluate the performance of OVA1 in a cohort of patients with low-risk serum
CA125 values. Study Design: We analyzed patient data from previous collections (N = 2305, preva-
lence = 4.5%) where CA125 levels were at or below 67 units/milliliter (U/mL) for pre-menopausal
women and 35 U/mL for post-menopausal women. We compare the performance of OVA1 to CA125
in classifying the risk of malignancy in this cohort, including sensitivity, specificity, positive and
negative predictive values. Results: The overall sensitivity of OVA1 in patients with a low-risk serum
CA125 was 59% with a false-positive rate of 30%. OVA1 detected over 50% of ovarian malignancies
in premenopausal women despite a low-risk serum CA125. OVA1 also correctly identified 63% of
early-stage cancers missed by CA125. The most common epithelial ovarian cancer subtypes in the
study population were mucinous (25%) and serous (23%) carcinomas. Despite a low-risk CA125,
OVA1 successfully detected 83% of serous, 58% of mucinous, and 50% of clear cell ovarian cancers.
Conclusions: As a standalone test, CA125 misses a significant number of ovarian malignancies that
can be detected by OVA1. This is particularly important for premenopausal women and early-stage
cancers, which have a much better long-term survival than late-stage malignancies. Using OVA1
in the setting of a normal serum CA125 can help identify at-risk ovarian tumors for referral to a
gynecologic oncologist, potentially improving overall survival.
Keywords: OVA1; CA125; ovarian malignancy; early-stage detection
1. Introduction
Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of
death in women. Although the incidence of ovarian cancer has declined in the past
30 years, the mortality rate remains high, with only half of women surviving longer than
five years [1]. There is no recommended screening test for ovarian cancer, so women
continue to present with advanced-stage disease where the prognosis is guarded [2]. Early
detection of ovarian cancer is paramount if we hope to improve disease outcomes, including
novel screening strategies and effective preoperative ovarian tumor evaluations.
Serum cancer antigen 125 (CA125) testing is only FDA-approved for monitoring
women during the treatment of ovarian cancer. Still, many clinicians continue to use it as an
off-label test to assess the risk of malignancy in women with an adnexal mass. While CA125
is an excellent marker for advanced-stage serous cancers, several ovarian cancer histological
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subtypes do not cause elevated CA125 levels, most notably mucinous carcinomas and non-
epithelial malignancies [3]. Moreover, many early-stage ovarian cancers do not produce
detectable levels of CA125 in the serum. For example, a 2014 analysis by Longoria et al.
showed that CA125 identified only 69% of stage I primary ovarian malignancies using the
CA125 cutoffs established by Dearking et al. (67 units/milliliter (U/mL) and 35 U/mL for
premenopausal and postmenopausal women, respectively) [4,5].
The OVA1 assay is an FDA-approved multivariate index assay composed of five
serum biomarkers, which collectively improve the detection of cancers missed by CA125
alone [6,7]. Each value is algorithmically composited into a unitless risk score between 1
and 10 to estimate the risk of malignancy of an adnexal mass that is scheduled for surgical
removal [6,7]. Overall, the sensitivity of the multivariate OVA1 assay is 92% compared
to 79% for CA125 testing alone [6]. In early-stage primary ovarian malignancies, the
sensitivities are 91% and 73%, respectively [6]. In the pivotal OVA1 trial published in 2011,
OVA1 identified 76% of malignancies missed by CA125 [7].
In this investigation, we evaluate the ability of the OVA1 multivariate assay to salvage
detection of cancers in a cohort of patients in which CA125 is non-informative due to
low-risk or “normal” serum values.
2. Materials and Methods
For this investigation, the authors reviewed clinical outcomes and serum biomarker
data from five previous studies in the United States. These specimens were collected
between 2009 and 2020 for clinical validation and independent verification of OVA1. The
previous site collections were done according to five different protocols, including OVA1-
001-CO1, OVA2-002-CO3, OVA1-7788, OVA1-PS1-CO4, and RP 01-2016. The purpose
of each collection has previously been reported [6–9]. Each site independently obtained
Institutional Review Board approval. Study inclusion criteria were the same at all locations,
including women over 18 years undergoing surgical removal of an adnexal mass.
The authors merged the prospectively collected data for this retrospective analysis.
Patients were eligible for inclusion in this study if the serum CA125 value was below the
“high-risk” cutoff as established by Dearking et al. (67 U/mL premenopausal; 35 U/mL
postmenopausal [5]). The analysis included tumors with malignant and benign pathology
but did not include low malignant potential (borderline) tumors.
OVA1 is a multivariate index assay that incorporates transferrin, transthyretin (preal-
bumin), beta-2 microglobulin, apolipoprotein A-1, and CA125 (assays by Roche Diagnostics,
Indianapolis, IN, USA). These markers were chosen to work in concert with proteins that
were found to capture data patterns that would pick up malignancies missed by CA125
or reduce false-positives [10]. The algorithm combines the five biomarkers to generate a
unitless risk score between 0 and 10 [6] (OvaCalc 3.0.3, Aspira Women’s Health, Austin,
TX, USA). The risk of malignancy cutoffs are stratified as follows:
• Premenopausal women: ≥5.0 is elevated risk for malignancy
• Postmenopausal women: ≥4.4 is elevated risk for malignancy
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value
(NPV) were calculated for OVA1 and stratified by various subgroups. Statistics were
calculated using the DTComPair package (version 1.0.3) of the R programming language
(version 4.0.2, GNU GPL license).
3. Results
Of the 2305 patients with low-risk CA125 values, 104 were diagnosed with malignancy
on final pathology (4.5% prevalence). Table 1 summarizes the clinical characteristics of the
study population. Primary ovarian cancers accounted for 75 of the 104 malignancies (72%).
The remaining 29 cancers included tumors metastatic to the ovary (9) and non-ovarian
pelvic malignancies with no ovarian involvement (20). In patients diagnosed with cancer,
OVA1 was high-risk in 61/104 (59% sensitivity; true-positive rate) and low-risk in 43 (41%
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false-negative rate). In patients with benign disease on final pathology, OVA1 was low-risk in
1548/2201 and high-risk in 653 (70% specificity, 97% NPV), with a false-positive rate of 30%.








N % N % N %
White/Caucasian 1492 64.73% 848 64.98% 644 64.40%
Black/African American 278 12.06% 192 14.71% 86 8.60%
Hispanic/Latinx 181 7.85% 128 9.81% 53 5.30%
Asian 34 1.48% 24 1.84% 10 1.00%
Native American 7 0.30% 4 0.31% 3 0.30%
Native Hawaiian/Pacific Islander 8 0.35% 6 0.46% 2 0.20%
Other 20 0.87% 13 1.00% 7 0.70%
Unspecified 285 12.36% 90 6.90% 195 19.50%
Pathology Diagnosis
Benign 2201 95.49% 1266 97.01% 935 93.50%
Primary ovarian malignancy 75 3.25% 27 2.07% 48 4.80%
Non-primary, metastatic to ovary 9 0.39% 4 0.31% 5 0.50%
Non-primary, not metastatic to ovary 20 0.87% 8 0.61% 12 1.20%
Stage (Primary Ovarian Malignancies)
Stage I 37 49.33% 16 59.26% 21 43.75%
Stage II 4 5.33% 1 3.70% 3 6.25%
Stage III 11 14.67% 2 7.41% 9 18.75%
Stage IV 6 8.00% 0 0.00% 6 12.50%
Not Staged 17 22.67% 8 29.63% 9 18.75%
Histological Subtype (Primary Ovarian Malignancies)
Serous 17 22.67% 4 14.81% 13 27.08%
Mucinous 19 25.33% 8 29.63% 11 22.92%
Clear cell 8 10.67% 1 3.70% 7 14.58%
Endometrioid 3 4.00% 1 3.70% 2 4.17%
Carcinosarcoma 2 2.67% 0 0.00% 2 4.17%
Carcinoid 2 2.67% 1 3.70% 1 2.08%
Mixed 1 1.33% 0 0.00% 1 2.08%
Poorly differentiated 1 1.33% 0 0.00% 1 2.08%
Other epithelial cancer 1 1.33% 0 0.00% 1 2.08%
Germ cell 1 1.33% 1 3.70% 0 0.00%
Sex cord Stromal 8 10.67% 4 14.81% 4 8.33%
Granulosa cell tumor 10 13.33% 5 18.52% 5 10.42%
Other non-epithelial cancer 2 2.67% 2 7.41% 0 0.00%
* Low-risk CA125, 67 U/mL for premenopausa; 35 U/mL for postmenopausal or unknown. ** Includes patients with unspecified
menopausal status.
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Table 2 summarizes the influence of menopausal status on the performance of OVA1.
For premenopausal women with a low-risk CA125 diagnosed with malignancy, the sensi-
tivity and specificity of OVA1 were 51% and 77%, respectively. In postmenopausal women,
OVA1 salvaged detection in 63% of the cancers which CA125 did not detect. Specificity was
61%, with PPV and NPV of 10% and 96%, respectively. In patients with benign disease on fi-
nal pathology, OVA1 was low-risk in 980/1266 premenopausal women (77% specificity, 98%
NPV) and 568/935 postmenopausal women (61% specificity, 96% NPV). The false-positive
rate for premenopausal women was 23% and 39% for postmenopausal women.
Table 2. Clinical performance summary of OVA1 in low-risk CA125 patients.
OVA1 Performance When CA125 Is Low-Risk *
N Sensitivity (%, n/N) Specificity (%, n/N) PPV (%, n/N) NPV (%, n/N)
All women 2305 58.65% 70.33% 8.54% 97.30%61/104 1548/2201 61/714 1548/1591
Pre-menopausal 1305 51.28% 77.41% 6.54% 98.10%20/39 980/1266 20/306 980/999
Post-menopausal or unknown 1000 63.08% 60.75% 10.05% 95.95%41/65 568/935 41/408 568/592
Early-stage (I and II) 41 63.41%26/41
Late-stage (III and IV) 17 76.47%13/17
Not staged 17 41.18%7/17
PPV, positive predictive value; NPV, negative predictive value. Cancer prevalence is 4.5% (104/2305). * Low-risk CA125, 67 U/mL for
premenopausal subjects; 35 U/mL for postmenopausal or unknown subjects.
Of the 75 primary ovarian cancers missed by CA125 testing alone, 58 had comprehen-
sive staging. There were 41 early-stage (37 stage I; 4 stage II) and 17 advanced-stage cancers
(11 stage 3; 6 stage 4). OVA1 was able to salvage detection in 63% (26/41) of early-stage
cancers in which CA125 failed to detect malignancy, including 60% (22/37) of stage I and
100% (4/4) of stage 2 cancers (Table 2).
Since there is evidence in the literature to suggest that baseline CA125 levels may vary
between racial groups [11–14], we examined the performance of OVA1 stratified by race
(Table 3). Sixty-five white/Caucasian and twelve Black/African American women had
cancer and a low-risk serum CA125. We excluded Hispanic/Latino and Asian populations
from the individual race analysis because of the small sample size. For patients with a low-
risk CA125, the sensitivity of OVA1 in white women was 65% versus 42% in Black women.
Conversely, the specificity of OVA1 was higher in Black (79%) than in white women (68%).
Positive and negative predictive values were similar. Likelihood ratios have also been
provided. The positive likelihood ratio, LR+, shows the probability that an individual
with a malignant adnexal mass will have an elevated risk OVA1 result compared to an
individual with a benign mass. The negative likelihood ratio, LR−, shows the probability
of an individual with a malignancy having a low-risk OVA1 result compared to one with a
benign mass. For both Black and white women, these ratios were similar, though the LR−
reflects the reduced sensitivity in Black women.
Table 4 shows the association between tumor histology and OVA1. When the CA125
was low-risk, OVA1 successfully detected serous carcinomas in 14/17 subjects (82%) and
mucinous and clear cell cancers in 11/19 (58%) and 4/8 (50%), respectively. In addition to
detecting epithelial ovarian cancer, OVA1 identified over half (5/8, 62%) of sex cord-stromal
tumors and 40% (4/10) of granulosa cell tumors.
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Table 3. OVA1 Performance Stratified by Race.
OVA1 Performance When CA125 Is Low-Risk * by Race
Menopausal Status N Sensitivity(%, n/N)
Specificity
(%, n/N) PPV (%, n/N) NPV (%, n/N) LR+ LR−
White/Caucasian
All 1492 64.62% 67.90% 8.40% 97.68% 2.01 0.5242/65 969/1427 42/500 969/992
Pre 848 54.55% 75.18% 5.53% 98.42% 2.20 0.6012/22 621/826 12/217 621/631
Post 644 69.77% 57.90% 10.60% 96.40% 1.66 0.5230/43 348/601 30/283 348/361
Black/African
American
All 283 41.67% 79.32% 8.33% 96.79% 2.02 0.745/12 211/266 5/60 211/218
Pre 195 37.50% 82.07% 8.33% 96.79% 2.09 0.763/8 151/184 3/36 151/156
Post 88 50.00% 73.17% 8.33% 96.77% 1.86 0.682/4 60/82 2/24 60/62
PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio. Cancer
prevalence is 4.5% (104/2305). * Low-risk CA125, 67 U/mL for premenopausal subjects; 35 U/mL for postmenopausal or unknown subjects.
Table 4. OVA1 Performance by Histological Subtype and FIGO Stage When Low-Risk CA125 *.
OVA1 n/N
Histological Subtype All Stage I Stage II Stage III Stage IV Not Staged
Serous 14/17 2/2 2/2 5/5 4/5 1/3
Mucinous 11/19 7/13 2/3 2/3
Clear cell 4/8 3/4 0/2 1/2
Endometrioid 1/3 1/2 0/1
Carcinosarcoma 2/2 1/1 1/1
Carcinoid 0/2 0/1 0/1
Mixed 1/1 1/1
Poorly differentiated 1/1 1/1
Other epithelial cancer 1/1 1/1
Germ cell 1/1 1/1
Sex cord stromal 5/8 3/5 1/1 1/2
Granulosa cell tumor 4/10 3/6 1/4
Other non-epithelial cancer 1/2 1/2
* Low-risk CA125, 67 U/mL for premenopausal subjects; 35 U/mL for postmenopausal or unknown subjects.
4. Discussion
The results of this investigation demonstrate that even if the CA125 is low-risk, OVA1
can effectively identify ovarian malignancies. OVA1 integrates CA125 with additional
serum biomarkers to improve test sensitivity. High sensitivity helps OVA1 identify ovar-
ian malignancies where CA125 frequently fails, like early-stage disease, premenopausal
women, and several histologic subtypes, including mucinous, clear cell, and sex cord-
stromal tumors (Table 1). Since serum CA125 alone is unreliable for determining the
malignancy risk of an ovarian tumor [15–20], it is not recommended for use as a preopera-
tive test.
The current guidelines published by the American College of Obstetricians and Gy-
necologists (ACOG) no longer recommend a specific CA125 cutoff value for use in pre-
menopausal women [18]. Instead, the guidelines refer to a “very elevated” CA125 for
premenopausal women, while the previously published ACOG recommendation was
CA125 over 200 U/mL. Since CA125 is not approved for use as a preoperative test and
ACOG recommends no specific premenopausal cutoff value, CA125 has a limited role in
this cohort. When used as a preoperative test, a false-negative CA125 may adversely affect
patient outcomes through missed cancer diagnoses, deferred referral to a cancer specialist,
delayed surgical intervention, and repeat operations. This study evaluates the performance
of OVA1 using a conservative CA125 cutoff of 67 U/mL [5], yet CA125 still fails to detect
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primary ovarian cancer in 39 premenopausal and 65 postmenopausal women. Conversely,
OVA1 salvaged the detection of 51% (20/39) of premenopausal cancers and 63% (41/65) of
postmenopausal cancers for which CA125 failed to detect malignancy.
The overall test sensitivity of OVA1 in detecting ovarian malignancy has previously
been reported to exceed 90% [4,6,7], while serum CA125’s high sensitivity is limited to
advanced-stage, high-grade serous ovarian cancers [19,20]. The advantage of a multivariate
index assay like OVA1 is its ability to detect ovarian malignancies when CA125 is within
the normal range. This is particularly critical for early-stage ovarian malignancies and
premenopausal women, where appropriate treatment can result in favorable long-term
outcomes. The five-year survival for stage I ovarian cancer exceeds 90% (75% for stage II
disease) when treated by a gynecologic oncologist [21,22], compared to less than 50% for
advanced-stage disease. However, since early-stage ovarian cancer is frequently asymp-
tomatic, or symptoms are easily attributed to common conditions, diagnosis and referral
are often delayed. In this study, OVA1 identified 63% (26/41) of early-stage primary
ovarian malignancies missed by CA125. Similarly, Longoria et al. reported that OVA1
detected 78% of early-stage ovarian cancers missed by CA125 [4]. Therefore, a multivariate
test like OVA1 may help clinicians identify more early-stage ovarian cancers for referral
to a gynecologic oncologist, increasing the likelihood of proper treatment and improved
long-term survival [23,24].
As a predictive and prognostic biomarker for ovarian cancer, sensitivity and specificity
vary by histologic subtype [25]. Serum CA125 levels are frequently normal for ovarian
malignancies of non-serous histology, especially for mucinous cancers where the true-
positive rate is only 12% [25]. OVA1 identified at least half of clear cell (4/8, 50%) and
mucinous (11/19, 58%) ovarian carcinomas missed by CA125, a promising result for these
challenging cell types. Like serous cancers, early detection of mucinous and clear cell
ovarian cancers confers a better prognosis, while the survival rate for late-stage cancers is
guarded [26]. Half of all sex cord-stromal tumors (9/18) with a low-risk CA125 were also
successfully identified by OVA1, including 7/12 early-stage malignancies.
This investigation has several strengths. The data were extracted from five prospective
studies with similar inclusion criteria allowing for a large, homogenous study group with
limited information bias. All ovarian tumor types were included in these studies, and
most malignancies were appropriately staged. Biomarker testing was also independently
performed and validated, limiting measurement error bias. A limitation of this study is
the retrospective nature of the data analysis, which was performed after merging several
study databases. Additionally, the percentage of early-stage ovarian cancer in this study
(70%) is twice that expected in the general population, suggesting a possible sampling bias;
however, this shift toward early-stage cancers does allow for a more robust evaluation of
test performance in this cohort.
It is helpful to understand the impact of cancer prevalence on calculated predictive
values. Study populations with a low cancer prevalence will have a lower PPV and higher
NPV compared to a population of high prevalence. The OVA1 test performs with high
sensitivity and NPV, but lower cancer specificity than CA125. Since OVA1 is intended as
a first-line test for women with an adnexal mass that is planned for surgery, the test was
specifically engineered to have high sensitivity and high NPV to avoid missing cancers
(false-negative results). Missed cancers may require re-operation if an occult malignancy
is found unexpectedly at surgery by a non-specialist, or cancers may present in a more
advanced stage with potentially worse clinical outcomes. In this study population of
low-risk CA125, OVA1 demonstrated a false-positive rate of 30%; however, it correctly
identified 61/104 patients that were missed by CA125.
OVA1 is a sensitive multivariate biomarker test that can identify ovarian cancer
even when the CA125 is normal. The findings of this investigation support previous
publications [4,6,7] in concluding that OVA1 successfully identifies the majority of pelvic
malignancies (59%) and 63% of early-stage ovarian cancers that are missed by serum
CA125. Moreover, OVA1 identifies over half of the cancers in premenopausal women and
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non-serous ovarian malignancies when the CA125 is low-risk. OVA1 is a multivariate
index assay with high sensitivity that can identify ovarian malignancy in the setting of
a normal serum CA125 to help expedite surgical decisions and referral to a gynecologic
oncologist, improving appropriate treatment and overall survival.
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